Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|8|3|208-221

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.8, Iss.3, 2008-06, pp. : 208-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer

By  

Current Cancer Drug Targets, Vol. 7, Iss. 2, 2007-03 ,pp. : 169-174

Bentham Science Publishers

Access to resources Recommend Favorite

Replicating herpes simplex virus vectors for cancer gene therapy

By Yeung S.N.   Tufaro F.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses

By  

Current Cancer Drug Targets, Vol. 7, Iss. 2, 2007-03 ,pp. : 149-155

Bentham Science Publishers

Access to resources Recommend Favorite

Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery

By Gaston David C   Whitley Richard J   Parker Jacqueline N  

Future Virology, Vol. 6, Iss. 3, 2011-03 ,pp. : 321-340

Future Medicine

Access to resources Recommend Favorite

Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1

By  

Current Gene Therapy, Vol. 13, Iss. 6, 2013-12 ,pp. : 478-491

Bentham Science Publishers

Access to resources Recommend Favorite